PCRX logo

Pacira BioSciences (PCRX) Company Overview

Profile

Full Name:

Pacira BioSciences, Inc.

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

United States

IPO:

February 3, 2011

Indexes:

Not included

Website:

http://www.pacira.com

Description:

Pacira BioSciences, Inc. is a holding biopharmaceutical company headquartered in Parsippany-Troy Hills, New Jersey, operating through a number of subsidiaries. It was founded in 2006 as Blue Acquisition Corp. It is a leading provider of non-opioid pain relief medications for patients and physicians, as well as non-opioid solutions for surgeons and anesthesiologists in the field of health regeneration. Pacira BioSciences is the only supplier of long-acting non-opioid analgesics. The company's product portfolio includes the following medications: EXPAREL and the iovera system. In addition, the company has a range of products and solutions at various stages of clinical development, such as DepoDexmedetomidine, DepoFoam-based local anesthetic, Pediatric infiltration, Lower extremity nerve block, and others.

Key Details

Price

$23.41

Market Cap

$1.08 B(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$700.97 M(+3.85% YoY)

Annual EPS

-$2.15(-341.57% YoY)

PE Ratio

-

Annual ROE

-12.08%

Annual Debt To Equity

0.75

Beta

0.39

Events Calendar

Earnings

Next earnings date:

May 7, 2025

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 28, 25 Needham
Buy
Feb 28, 25 HC Wainwright & Co.
Buy
Feb 28, 25 Barclays
Overweight
Jan 30, 25 Truist Securities
Hold
Jan 14, 25 RBC Capital
Sector Perform
Jan 13, 25 Needham
Buy
Dec 17, 24 Needham
Buy
Dec 4, 24 HC Wainwright & Co.
Buy
Nov 12, 24 Barclays
Equal-Weight
Nov 8, 24 Needham
Buy

Screeners with PCRX included

US stocks
Stocks below analysts price target
Stocks recommended to hold
Best performing stocks last 3 months
Stocks above SMA 50
Healthcare sector
All stocks
Companies with buyback
Small cap stocks
Stocks with low beta

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$23.41
PCRX price is $23.41

Price All-time High

$119.27
PCRX price is currently -80.37% below its historical high of $119.27

Price Analysts Target

$25.00
PCRX price is currently -6.36% lower than the consensus analysts' forecast

Price Today Change

-2.66%
PCRX price is down -2.66% today

Price YTD Change

+24.26%
PCRX price is up +24.26% since January 1st

Price 3-Year Change

-67.32%
PCRX price is down -67.32% over the past 3 years

Market cap

Market Cap

$1.08 B
PCRX market capitalization is $1.08 billion

Market Cap 3-Year Change

-66.28%
PCRX market capitalization is down -66.28% over the past 3 years

Market Cap All-time High

$4.32 B
PCRX market capitalization is currently -74.93% below its historical high of $4.32 billion

Market Cap Sector Rank

75.33%
PCRX market capitalization is higher than 75.33% of companies in Healthcare sector

Technical

Beta

0.39
PCRX beta is 0.39

200-day SMA

$20.64
PCRX price is currently +13.45% above its 200-day simple moving average

14-day RSI

43.90
PCRX 14-day relative strength index is 43.90

30-day Relative Volume

0.83
PCRX 30-day relative volume is 0.83

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$700.97 M
PCRX annual revenue is $700.97 million

Annual Revenue Analysts Estimate

$750.93 M
PCRX annual revenue is currently -6.65% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+3.85%
PCRX annual revenue is up +3.85% year-on-year

Annual Revenue Sector Rank

77.35%
PCRX annual revenue is higher than 77.35% of companies in Healthcare sector

Profit

Annual Gross Profit

$530.54 M
PCRX annual gross profit is $530.54 million

Annual Gross Margin

75.69%
PCRX annual gross profit margin is 75.69%

Annual Operating Profit

$97.57 M
PCRX annual operating income is $97.57 million

Annual Operating Margin

13.92%
PCRX annual operating profit margin is 13.92%

Annual Net Income

-$99.56 M
PCRX annual net profit is -$99.56 million

Annual Net Margin

-14.20%
PCRX annual net profit margin is -14.20%

EPS

Annual EPS

-$2.15
PCRX annual earnings per share is -$2.15

Annual EPS Analysts Estimate

$2.81
PCRX annual earnings per share is currently -176.51% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

-341.57%
PCRX annual earnings per share is down -341.57% year-on-year

Annual EPS Sector Rank

40.18%
PCRX annual earnings per share is higher than 40.18% of companies in Healthcare sector

ROA & ROE

Annual ROA

-6.37%
PCRX annual return on assets is -6.37%

Annual ROE

-12.08%
PCRX annual return on equity is -12.08%

EBIT & EBITDA

Annual EBIT

-$49.67 M
PCRX annual earnings before interest & taxes is -$49.67 million

Annual EBITDA

$29.12 M
PCRX annual EBITDA is $29.12 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
PCRX price to earnings ratio value is unknown

PE Ratio Sector Rank

-
PCRX price to earnings ratio is unknown

PB Ratio

PB Ratio

1.39
PCRX price to book ratio is 1.39

PB Ratio Sector Rank

50.12%
PCRX price to book ratio is higher than 50.12% of companies in Healthcare sector

PS Ratio

PS Ratio

1.55
PCRX price to sales ratio is 1.55

PS Ratio Sector Rank

33.85%
PCRX price to sales ratio is higher than 33.85% of companies in Healthcare sector

Enterprise value

Enterprise Value

$1.45 B
PCRX enterprise value is $1.45 billion

Enterprise Value Sector Rank

77.85%
PCRX enterprise value is higher than 77.85% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

49.64
PCRX EV/EBITDA is 49.64

EV/EBITDA Sector Rank

96.83%
PCRX EV/EBITDA is higher than 96.83% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

2.40
PCRX annual current ratio is 2.40

Annual Quick Ratio

2.00
PCRX annual quick ratio is 2.00

Leverage

Annual Debt To Equity

0.75
PCRX annual debt to equity ratio is 0.75

Annual Interest Coverage Ratio

-3.70
PCRX annual interest coverage ratio is -3.70

Risk & Stability

Piotroski F-Score

5
PCRX piotroski f-score is 5

Altman Z-Score

1.33
PCRX altman z-score is 1.33

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$1.55 B
PCRX annual total assets is $1.55 billion

Annual Non Current Assets

$808.39 M
PCRX annual long term assets is $808.39 million

Annual Current Assets

$745.13 M
PCRX annual total current assets is $745.13 million

Annual Cash & Cash Equivalents

$276.77 M
PCRX annual cash & cash equivalents is $276.77 million

Equity

Annual Book Value

$778.35 M
PCRX annual book value is $778.35 million

Annual Working Capital

$435.21 M
PCRX annual working capital is $435.21 million

Liabilities

Annual Total Liabilities

$775.17 M
PCRX annual total liabilities is $775.17 million

Annual Total Long Term Liabilities

$465.25 M
PCRX annual total long term liabilities is $465.25 million

Annual Current Liabilities

$309.92 M
PCRX annual total current liabilities is $309.92 million

Annual Accounts Payable

$19.13 M
PCRX annual accounts payable is $19.13 million

Debt

Annual Total Debt

$638.85 M
PCRX annual total debt is $638.85 million

Annual Total Debt 1-Year Change

+9.01%
PCRX annual total debt is up +9.01% year-on-year

Annual Long Term Debt

$428.19 M
PCRX annual long term debt is $428.19 million

Annual Short Term Debt

$210.66 M
PCRX annual short term debt is $210.66 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$603.39 M
PCRX annual total expenses is $603.39 million

Annual Operating Expenses

$432.96 M
PCRX annual total operating expenses is $432.96 million

Annual Cost Of Goods Sold

$170.43 M
PCRX annual cost of goods sold is $170.43 million

Annual SGA

$294.10 M
PCRX annual SGA is $294.10 million

Annual D&A

$78.78 M
PCRX annual depreciation & amortization is $78.78 million

Annual Interest Expense

$13.44 M
PCRX annual interest expense is $13.44 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$189.39 M
PCRX annual cash flow from operations is $189.39 million

Annual CFO 1-Year Change

+22.46%
PCRX annual cash flow from operations is up +22.46% year-on-year

Annual CFI

-$83.28 M
PCRX annual cash flow from investing activities is -$83.28 million

Annual CFI 1-Year Change

-207.4%
PCRX annual cash flow from investing activities is down -207.4% year-on-year

Annual CFF

$17.36 M
PCRX annual cash flow from financing activities is $17.36 million

Annual CFF 1-Year Change

+109.49%
PCRX annual cash flow from financing activities is up +109.49% year-on-year

Free CashFlow

Annual FCF

$178.75 M
PCRX annual free cash flow is $178.75 million

Annual FCF 1-Year Change

+28.15%
PCRX annual free cash flow is up +28.15% year-on-year

CAPEX

Annual CAPEX

$10.64 M
PCRX annual capital expenditures is $10.64 million

Annual CAPEX 1-Year Change

-29.85%
PCRX annual capital expenditures is down -29.85% year-on-year

Institutional Ownership

Similar stocks

BLFS logo
BioLife Solutions (BLFS)
INVA logo
Innoviva (INVA)
GERN logo
Geron (GERN)
OCUL logo
Ocular Therapeutix (OCUL)
AUPH logo
Aurinia Pharmaceuticals (AUPH)
FNA logo
Paragon 28 (FNA)
BKD logo
Brookdale Senior Living (BKD)
XNCR logo
Xencor (XNCR)
VIR logo
Vir Biotechnology (VIR)

FAQ

  • What is the ticker symbol for Pacira BioSciences?
  • Does Pacira BioSciences pay dividends?
  • What sector is Pacira BioSciences in?
  • What industry is Pacira BioSciences in?
  • What country is Pacira BioSciences based in?
  • When did Pacira BioSciences go public?
  • Is Pacira BioSciences in the S&P 500?
  • Is Pacira BioSciences in the NASDAQ 100?
  • Is Pacira BioSciences in the Dow Jones?
  • When was Pacira BioSciences's last earnings report?
  • When does Pacira BioSciences report earnings?
  • Should I buy Pacira BioSciences stock now?

What is the ticker symbol for Pacira BioSciences?

The ticker symbol for Pacira BioSciences is NASDAQ:PCRX

Does Pacira BioSciences pay dividends?

No, Pacira BioSciences does not pay dividends

What sector is Pacira BioSciences in?

Pacira BioSciences is in the Healthcare sector

What industry is Pacira BioSciences in?

Pacira BioSciences is in the Drug Manufacturers - Specialty & Generic industry

What country is Pacira BioSciences based in?

Pacira BioSciences is headquartered in United States

When did Pacira BioSciences go public?

Pacira BioSciences's initial public offering (IPO) was on February 3, 2011

Is Pacira BioSciences in the S&P 500?

No, Pacira BioSciences is not included in the S&P 500 index

Is Pacira BioSciences in the NASDAQ 100?

No, Pacira BioSciences is not included in the NASDAQ 100 index

Is Pacira BioSciences in the Dow Jones?

No, Pacira BioSciences is not included in the Dow Jones index

When was Pacira BioSciences's last earnings report?

Pacira BioSciences's most recent earnings report was on Feb 27, 2025

When does Pacira BioSciences report earnings?

The next expected earnings date for Pacira BioSciences is May 7, 2025

Should I buy Pacira BioSciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions